Bioengineering of noncoding RNAs for research agents and therapeutics

Wiley Interdisciplinary Reviews: RNA

Volumn 7, Issue 2, 2016, Pages 186-197

  Ho, Pui Yan ^a   Yu, Ai Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOENGINEERED NCRNA AGENT; OPTIMAL NCRNA SCAFFOLD; RECOMBINANT RNA; RIBOSOME RNA; RNA BINDING PROTEIN; SMALL INTERFERING RNA; TRANSFER RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

BIOENGINEERING; DRUG RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; RNA STRUCTURE; RNA SYNTHESIS; RNA TRANSCRIPTION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; METABOLISM; RESEARCH; RNA GENE; SYNTHESIS;

ANIMALS; BIOENGINEERING; DRUG DISCOVERY; GENES, RRNA; HUMANS; IN VITRO TECHNIQUES; RESEARCH; RNA, SMALL INTERFERING; RNA, TRANSFER; RNA, UNTRANSLATED; RNA-BINDING PROTEINS;

EID: 84958943246     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.1324     Document Type: Review

References (69)

1. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
3. Gou LT, Dai P, Liu MF. Small noncoding RNAs and male infertility. WIREs RNA 2014, 5:733-745.
4. Snead NM, Rossi JJ. Biogenesis and function of endogenous and exogenous siRNAs. WIREs RNA 2010, 1:117-131.
5. Shah MY, Calin GA. MicroRNAs as therapeutic targets in human cancers. WIREs RNA 2014, 5:537-548.
6. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015, 87:108-119.
7. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012, 3:120.
8. Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998, 4:14-16.
9. Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006, 23:1403-1413.
10. Smith RJ, Hiatt WR. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. JAMA Intern Med 2013, 173:1491-1492.
11. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5:123-132.
12. Adams D, Cauquil C, Theaudin M, Rousseau A, Algalarrondo V, Slama MS. Current and future treatment of amyloid neuropathies. Expert Rev Neurother 2014, 14:1437-1451.
13. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383:60-68.
14. Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer((R)) therapeutics. Drug Discov Today 2015, 20:147-155.
15. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
16. Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 2015, 81:128-141.
17. Dahlman JE, Kauffman KJ, Langer R, Anderson DG. Nanotechnology for in vivo targeted siRNA delivery. Adv Genet 2014, 88:37-69.
18. Marshall WS, Kaiser RJ. Recent advances in the high-speed solid phase synthesis of RNA. Curr Opin Chem Biol 2004, 8:222-229.
19. Milligan J, Groebe D, Witherell G, Uhlenbeck O. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res 1987, 15:8783-8798.
20. Beckert B, Masquida B. Synthesis of RNA by in vitro transcription. Methods Mol Biol 2011, 703:29-41.
21. Ponchon L, Beauvais G, Nonin-Lecomte S, Dardel F. A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc 2009, 4:947-959.
22. Ponchon L, Dardel F. Recombinant RNA technology: the tRNA scaffold. Nat Methods 2007, 4:571-576.
23. Liu Y, Stepanov VG, Strych U, Willson RC, Jackson GW, Fox GE. DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli. BMC Biotechnol 2010, 10:85.
24. Chen QX, Wang WP, Zeng S, Urayama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res 2015, 43:3857-3869.
25. Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, et al. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization. J Pharmacol Exp Ther 2015, 354:131-141.
26. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
27. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010, 50:259-293.
28. Sanghvi YS. Chapter 4: A status update of modified oligonucleotides for chemotherapeutics applications. In: Current Protocols in Nucleic Acids Chemistry. 2011, Unit 4:1-22.
29. Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 2010, 5:328-349.
30. Obernosterer G, Martinez J, Alenius M. Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections. Nat Protoc 2007, 2:1508-1514.
31. Dunin-Horkawicz S, Czerwoniec A, Gajda MJ, Feder M, Grosjean H, Bujnicki JM. MODOMICS: a database of RNA modification pathways. Nucleic Acids Res 2006, 34:D145-D149.
32. Machnicka MA, Milanowska K, Osman Oglou O, Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S, Dunin-Horkawicz S, Rother KM, et al. MODOMICS: a database of RNA modification pathways-2013 update. Nucleic Acids Res 2013, 41:D262-D267.
33. Limbach PA, Crain PF, McCloskey JA. Summary: the modified nucleosides of RNA. Nucleic Acids Res 1994, 22:2183-2196.
34. Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, Vendeix FA, Fabris D, Agris PF. The RNA modification database, RNAMDB: 2011 update. Nucleic Acids Res 2011, 39:D195-D201.
35. Helm M. Post-transcriptional nucleotide modification and alternative folding of RNA. Nucleic Acids Res 2006, 34:721-733.
36. Phelps K, Morris A, Beal PA. Novel modifications in RNA. ACS Chem Biol 2012, 7:100-109.
37. Kariko K, Weissman D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development. Curr Opin Drug Discov Dev 2007, 10:523-532.
38. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001, 413:732-738.
39. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
40. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
41. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
42. Huang L, Jin J, Deighan P, Kiner E, McReynolds L, Lieberman J. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol 2013, 31:350-356.
43. Zhang X, Potty AS, Jackson GW, Stepanov V, Tang A, Liu Y, Kourentzi K, Strych U, Fox GE, Willson RC. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit 2009, 22:154-161.
44. Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Chimeric microRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos 2015, 43:1129-1136.
45. Pleiss JA, Derrick ML, Uhlenbeck O. T7 RNA polymerase produces 5′ end heterogeneity during in vitro transcription from certain templates. RNA 1998, 4:1313-1317.
46. Gardner LP, Mookhtiar KA, Coleman JE. Initiation, elongation, and processivity of carboxyl-terminal mutants of T7 RNA polymerase. Biochemistry 1997, 36:2908-2918.
47. Wons E, Furmanek-Blaszk B, Sektas M. RNA editing by T7 RNA polymerase bypasses InDel mutations causing unexpected phenotypic changes. Nucleic Acids Res 2015, 43:3950-3963.
48. Yang D, Buchholz F, Huang Z, Goga A, Chen CY, Brodsky FM, Bishop JM. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci USA 2002, 99:9942-9947.
49. Wianny F, Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol 2000, 2:70-75.
50. Myers JW, Jones JT, Meyer T, Ferrell JE Jr. Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat Biotechnol 2003, 21:324-328.
51. Guiley KZ, Pratt AJ, MacRae IJ. Single-pot enzymatic synthesis of Dicer-substrate siRNAs. Nucleic Acids Res 2012, 40:e40.
52. Qiu W, Park JW, Scholthof HB. Tombusvirus P19-mediated suppression of virus-induced gene silencing is controlled by genetic and dosage features that influence pathogenicity. Mol Plant Microbe Interact 2002, 15:269-280.
53. Silhavy D, Molnar A, Lucioli A, Szittya G, Hornyik C, Tavazza M, Burgyan J. A viral protein suppresses RNA silencing and binds silencing-generated, 21- to 25-nucleotide double-stranded RNAs. EMBO J 2002, 21:3070-3080.
54. Jin J, Cid M, Poole CB, McReynolds LA. Protein mediated miRNA detection and siRNA enrichment using p19. Biotechniques 2010, 48:xvii-xxiii.
55. Phizicky EM, Hopper AK. tRNA biology charges to the front. Genes Dev 2010, 24:1832-1860.
56. Sample PJ, Gaston KW, Alfonzo JD, Limbach PA. RoboOligo: software for mass spectrometry data to support manual and de novo sequencing of post-transcriptionally modified ribonucleic acids. Nucleic Acids Res 2015, 43:e64.
57. Jackman JE, Alfonzo JD. Transfer RNA modifications: nature's combinatorial chemistry playground. WIREs RNA 2013, 4:35-48.
58. Engelke DR, Hopper AK. Modified view of tRNA: stability amid sequence diversity. Mol Cell 2006, 21:144-145.
59. Meinnel T, Mechulam Y, Fayat G. Fast purification of a functional elongator tRNAmet expressed from a synthetic gene in vivo. Nucleic Acids Res 1988, 16:8095-8096.
60. Gaudin C, Nonin-Lecomte S, Tisné C, Corvaisier S, Bordeau V, Dardel F, Felden B. The tRNA-like domains of E. coli and A. aeolicus transfer-messenger RNA: structural and functional studies. J Mol Biol 2003, 331:457-471.
61. Paige JS, Wu KY, Jaffrey SR. RNA mimics of green fluorescent protein. Science 2011, 333:642-646.
62. Paige JS, Nguyen-Duc T, Song W, Jaffrey SR. Fluorescence imaging of cellular metabolites with RNA. Science 2012, 335:1194.
63. Nelissen FH, Leunissen EH, van de Laar L, Tessari M, Heus HA, Wijmenga SS. Fast production of homogeneous recombinant RNA-towards large-scale production of RNA. Nucleic Acids Res 2012, 40:e102.
64. Li MM, Wang WP, Wu WJ, Huang M, Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos 2014, 42:1791-1795.
65. Ponchon L, Catala M, Seijo B, El Khouri M, Dardel F, Nonin-Lecomte S, Tisne C. Co-expression of RNA-protein complexes in Escherichia coli and applications to RNA biology. Nucleic Acids Res 2013, 41:e150.
66. Pitulle C, Hedenstierna KO, Fox GE. A novel approach for monitoring genetically engineered microorganisms by using artificial, stable RNAs. Appl Environ Microbiol 1995, 61:3661-3666.
67. Pitulle C, Hedenstierna KO, Fox GE. Useful properties of restriction enzymes that recognize interrupted palindromes. Biotechniques 1996, 21:619-620, 622.
68. Pitulle C, Dsouza L, Fox GE. A low molecular weight artificial RNA of unique size with multiple probe target regions. Syst Appl Microbiol 1997, 20:133-136.
69. Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. MicroRNA pharmacoepigenetics: Posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. Drug Metab Dispos. In press.